These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 18448262)

  • 21. Perceived risk and interest in screening for lung cancer among current and former smokers.
    Hahn EJ; Rayens MK; Hopenhayn C; Christian WJ
    Res Nurs Health; 2006 Aug; 29(4):359-70. PubMed ID: 16847914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association between the anti-inflammatory protein CC10 and smoking status among participants in a chemoprevention trial.
    Chen J; Lam S; Pilon A; McWilliams A; Melby J; Szabo E
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):577-83. PubMed ID: 17372255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term benefit of smoking cessation in patients with coronary heart disease: estimates based on self-reported smoking data and serum cotinine measurements.
    Twardella D; Küpper-Nybelen J; Rothenbacher D; Hahmann H; Wüsten B; Brenner H
    Eur Heart J; 2004 Dec; 25(23):2101-8. PubMed ID: 15571825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction and cessation of cigarette smoking and risk of cancer: a cohort study of Korean men.
    Song YM; Sung J; Cho HJ
    J Clin Oncol; 2008 Nov; 26(31):5101-6. PubMed ID: 18838704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Smoking and lung cancer.
    Ozlü T; Bülbül Y
    Tuberk Toraks; 2005; 53(2):200-9. PubMed ID: 16100660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypotheses and fundamental study design characteristics for evaluating potential reduced-risk tobacco products. Part I: Heuristic.
    Murrelle L; Coggins CR; Gennings C; Carchman RA; Carter WH; Davies BD; Krauss MR; Lee PN; Schleef RR; Zedler BK; Heidbreder C
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):1-10. PubMed ID: 20018224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of smoking cessation and lifetime exposure on C-reactive protein.
    Hastie CE; Haw S; Pell JP
    Nicotine Tob Res; 2008 Apr; 10(4):637-42. PubMed ID: 18418786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Further considerations on the evaluation of potential reduced-risk tobacco products. Part II: Re-assessment of a heuristic using the CPS-II database.
    Murrelle L; Coggins CR; Gennings C; Carchman RA; Lee PN; Zedler BK; Heidbreder C
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):11-7. PubMed ID: 20018223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The hazards and benefits associated with smoking and smoking cessation in Asia: a meta-analysis of prospective studies.
    Nakamura K; Huxley R; Ansary-Moghaddam A; Woodward M
    Tob Control; 2009 Oct; 18(5):345-53. PubMed ID: 19617218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tobacco industry efforts undermining evidence linking secondhand smoke with cardiovascular disease.
    Tong EK; Glantz SA
    Circulation; 2007 Oct; 116(16):1845-54. PubMed ID: 17938301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Alcohol and smoking. The risk factors for the oral cavity].
    Weinstein RL; Francetti L; Maggiore E; Marchesi G
    Minerva Stomatol; 1996 Sep; 45(9):405-13. PubMed ID: 8999304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers.
    Abbasi F; Farin HM; Lamendola C; McGraw L; McLaughlin T; Reaven GM
    Metabolism; 2008 Aug; 57(8):1108-14. PubMed ID: 18640389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modelling the health benefits of smoking cessation in Japan.
    Avila-Tang E; Apelberg BJ; Yamaguchi N; Katanoda K; Sobue T; Samet JM
    Tob Control; 2009 Feb; 18(1):10-7. PubMed ID: 18728096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lung cancer in smokers and never-smokers].
    Helland A; Brustugun OT
    Tidsskr Nor Laegeforen; 2009 Sep; 129(18):1859-62. PubMed ID: 19844277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The physiological effects of smoking on the respiratory system.
    Milner D
    Nurs Times; 2004 Jun 15-21; 100(24):56-9. PubMed ID: 15224495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes.
    Yamagishi S; Matsui T; Nakamura K
    Med Hypotheses; 2008 Nov; 71(5):749-51. PubMed ID: 18710793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depressive symptoms and smokers' perceptions of lung cancer risk: moderating effects of tobacco dependence.
    Floyd AH; Westmaas JL; Targhetta V; Moyer A
    Addict Behav; 2009 Feb; 34(2):154-63. PubMed ID: 18977092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanistic modelling in large case-control studies of lung cancer risk from smoking.
    Heidenreich WF; Wellmann J; Jacob P; Wichmann HE
    Stat Med; 2002 Oct; 21(20):3055-70. PubMed ID: 12369081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced glycation end products and diabetic foot disease.
    Huijberts MS; Schaper NC; Schalkwijk CG
    Diabetes Metab Res Rev; 2008; 24 Suppl 1():S19-24. PubMed ID: 18442180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.